Zaixing Yang1, Zhiyu Zhang2, Baodong Qin1, Ping Wu1, Renqian Zhong1, Lin Zhou3, Yan Liang4. 1. Department of Laboratory Diagnostics, Changzheng Hospital, Second Military Medical University, Shanghai, China. 2. Department of VIP, Changzheng Hospital, Second Military Medical University, Shanghai, China. 3. Department of Laboratory Diagnostics, Changzheng Hospital, Second Military Medical University, Shanghai, China. lynnzhou36@163.com. 4. Department of Laboratory Diagnostics, Changzheng Hospital, Second Military Medical University, Shanghai, China. liangyan0829@163.com.
Abstract
BACKGROUND: Human epididymis protein 4 (HE4) is an available tumor biomarker for detecting ovarian cancer. However, it is unknown if serum HE4 could be a novel biomarker for diagnosis of lupus nephritis (LN) and chronic kidney disease (CKD) in patients with systemic lupus erythematosus (SLE). METHODS: This study enrolled 209 SLE patients, 75 patients with renal dysfunction without SLE and 32 healthy subjects. HE4 concentrations were analyzed by ELISA (enzyme-linked immunosorbent assay; Fujirebio Diagnostics, Sweden). The receiver operating characteristic (ROC) curves were constructed to assess diagnostic accuracy of HE4 for LN or CKD in SLE. RESULTS: Serum HE4 level was significantly higher in SLE patients than that in healthy controls (P < 0.001), especially for those with LN or CKD. It was also higher in patients with renal dysfunction without SLE than healthy controls (P < 0.001), while there was no significant difference between these patients and those with SLE with CKD (P = 0.73). Multivariate analysis showed significant association between increased HE4 and LN or CKD after controlling for confounders. ROC curves showed the cutoff values were 150.1 pM (sensitivity, 76.8%; specificity, 91.1%) for the diagnosis of LN in SLE and 233.9 pM (sensitivity, 92.9%; specificity, 93.5%) for CKD in SLE. CONCLUSIONS: Increased serum HE4 level is closely associated with the development of LN or CKD in SLE patients. Furthermore, it can be used as a novel and useful biomarker for diagnosis of LN or CKD.
BACKGROUND:Humanepididymis protein 4 (HE4) is an available tumor biomarker for detecting ovarian cancer. However, it is unknown if serum HE4 could be a novel biomarker for diagnosis of lupus nephritis (LN) and chronic kidney disease (CKD) in patients with systemic lupus erythematosus (SLE). METHODS: This study enrolled 209 SLEpatients, 75 patients with renal dysfunction without SLE and 32 healthy subjects. HE4 concentrations were analyzed by ELISA (enzyme-linked immunosorbent assay; Fujirebio Diagnostics, Sweden). The receiver operating characteristic (ROC) curves were constructed to assess diagnostic accuracy of HE4 for LN or CKD in SLE. RESULTS: Serum HE4 level was significantly higher in SLEpatients than that in healthy controls (P < 0.001), especially for those with LN or CKD. It was also higher in patients with renal dysfunction without SLE than healthy controls (P < 0.001), while there was no significant difference between these patients and those with SLE with CKD (P = 0.73). Multivariate analysis showed significant association between increased HE4 and LN or CKD after controlling for confounders. ROC curves showed the cutoff values were 150.1 pM (sensitivity, 76.8%; specificity, 91.1%) for the diagnosis of LN in SLE and 233.9 pM (sensitivity, 92.9%; specificity, 93.5%) for CKD in SLE. CONCLUSIONS: Increased serum HE4 level is closely associated with the development of LN or CKD in SLEpatients. Furthermore, it can be used as a novel and useful biomarker for diagnosis of LN or CKD.
Authors: Andrew S Levey; Kai-Uwe Eckardt; Yusuke Tsukamoto; Adeera Levin; Josef Coresh; Jerome Rossert; Dick De Zeeuw; Thomas H Hostetter; Norbert Lameire; Garabed Eknoyan Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: Antoni Sisó; Manuel Ramos-Casals; Albert Bové; Pilar Brito-Zerón; Natalia Soria; Norma Nardi; Adriana Testi; Marta Perez-de-Lis; Cándido Díaz-Lagares; Alejandro Darnell; Juan Sentís; Antonio Coca Journal: Medicine (Baltimore) Date: 2010-09 Impact factor: 1.889
Authors: Heather N Reich; Dafna D Gladman; Murray B Urowitz; Joanne M Bargman; Michelle A Hladunewich; Wendy Lou; Steve C P Fan; Jiandong Su; Andrew M Herzenberg; Daniel C Cattran; Joan Wither; Carol Landolt-Marticorena; James W Scholey; Paul R Fortin Journal: Kidney Int Date: 2011-01-19 Impact factor: 10.612
Authors: M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Drescher; Pamela Paley; Nicole Urban Journal: Gynecol Oncol Date: 2009-11-28 Impact factor: 5.482
Authors: Lynne Bingle; Simon S Cross; Alec S High; William A Wallace; Doris Rassl; Guanglu Yuan; Ingegerd Hellstrom; Michael A Campos; Colin D Bingle Journal: Respir Res Date: 2006-04-06
Authors: K Huhtinen; P Suvitie; J Hiissa; J Junnila; J Huvila; H Kujari; M Setälä; P Härkki; J Jalkanen; J Fraser; J Mäkinen; A Auranen; M Poutanen; A Perheentupa Journal: Br J Cancer Date: 2009-03-31 Impact factor: 7.640